ERAS - Latest News
Erasca, Inc. (ERAS), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $5.13B. Beta to the broader market is 0.62.
The article list below shows the most recent ERAS headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent ERAS Headlines
Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower
seekingalpha.com - Oct 5, 2026
Erasca (ERAS) is now a fully funded fast follower in RAS-targeted oncology, with ~$1B pro forma liquidity and three potential registration-enabling tr
Erasca, Inc. (NASDAQ:ERAS) Stock Has Consensus Target Price of $22.09
defenseworld.net - Oct 3, 2026
Erasca, Inc. (NASDAQ: ERAS - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are currently
ERASCA, INC. (NASDAQ: ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
globenewswire.com - Sep 22, 2026
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investig
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
globenewswire.com - Sep 22, 2026
New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2. 5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Develop
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
globenewswire.com - Sep 21, 2026
SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of
How News Affects ERAS Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track ERAS's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked ERAS news questions
- What is the latest ERAS news headline?
- The most recent ERAS headline (Oct 5, 2026) is "Erasca: Revolution's Approval Just Took Risk Out Of The Fast Follower". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the ERAS news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What ERAS news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual ERAS options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.